logo

For the Inventor, By the Inventor

Santa Monica, CA, United States of America

Kite Pharma, Inc.


USPTO Granted Patents = 51



Trademarks = 21

Forward Citations = 92

Loading Chart...
Loading Chart...

62 inventors (with patents filed for the assignee):

goldMedal Stuart A Sievers (15 out of 17 patents)

silverMedal Adrian I Bot (11 out of 11 patents)

bronzeMedal Jed Wiltzius (11 out of 12 patents)

4.  Jed J W Wiltzius (7 out of 7 patents)

5.  Steven A Rosenberg (6 out of 148 patents)

6.  Ruben Alvarez Rodriguez (6 out of 7 patents)

7.  Jeffrey S Wiezorek (6 out of 7 patents)

8.  William Go (6 out of 7 patents)

9.  Rajul Jain (6 out of 7 patents)

10.  Jonathan Belk (5 out of 21 patents)

11.  John M Rossi (5 out of 5 patents)

12.  James Noble Kochenderfer (5 out of 30 patents)

13.  Peter Emtage (4 out of 15 patents)

14.  Gabrielle Romain (3 out of 3 patents)

15.  Sarah Wyman (3 out of 4 patents)


Core Competencies:
Chimeric Antigen Receptors
T Cell Therapy
Antigen Binding Molecules
Chimeric Polypeptides
T Cell Functionality
Prostate Cancer Treatments
Tumor Microenvironment
Soluble MHC Molecules
Modified Chimeric Receptors
BCMA Binding Molecules
CD70 Binding Molecules
Humanized Antigen-Binding Domains

51 patents:

1. 12736455 - Systems and methods for detecting suspended particles in fluids (2026-09-15),
2. D1147437 - Cassette rack (2026-09-08),
3. 12715925 - Methods of administering chimeric antigen receptor immunotherapy (2026-08-25),
4. 12709639 - METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY (2026-08-18),
5. 12630603 - Chimeric antigen receptor T cell therapy (2026-05-19),
6. 12600775 - Chimeric antigen receptor T cell therapy (2026-04-14),
7. 12583923 - CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE (2026-03-24),
8. 12551530 - IMMUNE CELL FUNCTION (2026-02-17),
9. 12540196 - GPC3 BINDING MOLECULES (2026-02-03),
10. 12480951 - METHODS AND COMPOSITIONS FOR T CELL THERAPY (2025-11-25),
11. D1102621 - Cassette rack (2025-11-18),
12. 12459979 - Modified chimeric antigen receptors and methods of use (2025-11-04),
13. 12458654 - Methods of conditioning patients for T cell therapy (2025-11-04),
14. 12454563 - Immune cell function (2025-10-28),
15. 12404305 - Chimeric polypeptides and uses thereof (2025-09-02),
Kite Pharma, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cancer immunotherapies. Their vision is to make a significant and transformational impact on cancer patients by advancing the field of cell therapy. Kite Pharma is dedicated to unlocking the power of the immune system through their engineered cell therapies, with a particular emphasis on chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies. They strive to bring life-saving treatments to patients with various types of cancers, utilizing their expertise in research, development, and manufacturing of cell therapies.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Kite Pharma, Inc.
51 Patents

#12 in Santa Monica, CA

#1,615 in California

#6,872 in US

#13,739 in the World

Santa Monica, CA (US)
Santa Monica, CA, United States of America

Kite Pharma, Inc.

Forward Citations = 92

62 inventors:

goldMedal Stuart A Sievers (15 out of 17 patents)

silverMedal Adrian I Bot (11 out of 11 patents)

bronzeMedal Jed Wiltzius (11 out of 12 patents)

4.  Jed J W Wiltzius (7 out of 7 patents)

5.  Steven A Rosenberg (6 out of 148 patents)

Please report any incorrect information to [email protected]
Loading…